Showing 4661-4670 of 5964 results for "".
- Aczone 7.5% Gel Now Approved Down to Age 9https://practicaldermatology.com/news/aczone-75-gel-now-approved-down-to-age-9/2460144/The FDA has approved the expanded indication for Almirall’s Aczone® 7.5% Gel to include patients aged 9-11. Aczone 7.5% Gel was previously approved in February 2016 to treat inflammatory and non-inflammatory acne in patients 12 and older. The expanded approval was based
- Skin Cancer Foundation Champions for Change Gala Coming in Octoberhttps://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-coming-in-october/2460142/The Skin Cancer Foundation’s annual Champions for Change Gala comes to The Plaza New York City October 17. The Champions for Change Gala is the signature fundraising event for The Skin Cancer Foundation’s programs and initiatives. Awards a
- Newly Created Lancer Endowed Chair of Dermatology Honors Dr. Richard Rox Andersonhttps://practicaldermatology.com/news/newly-created-lancer-endowed-chair-of-dermatology-honors-dr-richard-rox-anderson/2460141/The inaugural Lancer Endowed Chair of Dermatology at Massachusetts General Hospital (MGH) is Richard Rox Anderson, MD, director of the MGH Wellman Center for Photomedicine. The Lancer Endowed Chair was announced on Sep. 4, 2019 by Harold Lancer, MD at the Paul S. Russell,
- DermTech Closes Combination with Constellation Alpha Capital Corphttps://practicaldermatology.com/news/dermtech-closes-combination-with-constellation-alpha-capital-corp/2460138/DermTech, Inc., a precision dermatology company enabled by a non-invasive skin genomics platform, has completed its previously announced business combination with Constellation Alpha Capital Corp., a publicly traded special purpose acquisition company prior to the business combination. As a resul
- Amgen To Acquire Otezla® For $13.4 Billion In Cashhttps://practicaldermatology.com/news/amgen-to-acquire-otezla-for-134-billion-in-cash/2460135/Amgen has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company </
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS
- Europe Grants DefenAge Skincare Master Patenthttps://practicaldermatology.com/news/europe-grants-defenage-skincare-master-patent/2460132/DefenAge Skincare now has a master patent from the European Patent Office that covers DefenAge’s core technology. The patent protects the exclusive rights of DefenAge to use the spectrum of immune peptides called defensins in topical cosmetic formulations in a specific range of co
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identifie
- Study Shows StrataGraft-treated Deep Partial-thickness Burns Did Not Require Surgical Harvest of Healthy Skinhttps://practicaldermatology.com/news/study-shows-stratagraft-treated-deep-partial-thickness-burns-did-not-require-surgical-harvest-of-healthy-skin/2460127/Mallinckrodt plc shared results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries (ISBI). Study data showed that treatment with a single application of StrataGraft tissue resulted in